Cypress Asset Management Inc. TX decreased its stake in Pfizer Inc. (NYSE:PFE) by 0.9% during the third quarter, Holdings Channel reports. The institutional investor owned 55,940 shares of the biopharmaceutical company’s stock after selling 510 shares during the quarter. Cypress Asset Management Inc. TX’s holdings in Pfizer were worth $2,010,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds also recently modified their holdings of the company. Bath Savings Trust Co boosted its position in Pfizer by 3.4% during the second quarter. Bath Savings Trust Co now owns 17,217 shares of the biopharmaceutical company’s stock worth $746,000 after purchasing an additional 564 shares in the last quarter. Cox Capital Mgt LLC increased its holdings in shares of Pfizer by 1.5% in the second quarter. Cox Capital Mgt LLC now owns 37,986 shares of the biopharmaceutical company’s stock valued at $1,646,000 after purchasing an additional 565 shares during the last quarter. Thomasville National Bank increased its holdings in shares of Pfizer by 4.1% in the second quarter. Thomasville National Bank now owns 76,628 shares of the biopharmaceutical company’s stock valued at $3,319,000 after purchasing an additional 3,001 shares during the last quarter. Park National Corp OH increased its holdings in shares of Pfizer by 27.6% in the second quarter. Park National Corp OH now owns 252,546 shares of the biopharmaceutical company’s stock valued at $10,941,000 after purchasing an additional 54,642 shares during the last quarter. Finally, Deane Retirement Strategies Inc. increased its holdings in shares of Pfizer by 1.8% in the second quarter. Deane Retirement Strategies Inc. now owns 51,699 shares of the biopharmaceutical company’s stock valued at $2,240,000 after purchasing an additional 894 shares during the last quarter. Hedge funds and other institutional investors own 71.66% of the company’s stock.
In other news, Director Scott Gottlieb acquired 3,000 shares of the company’s stock in a transaction dated Friday, August 23rd. The stock was acquired at an average cost of $34.72 per share, with a total value of $104,160.00. Following the completion of the purchase, the director now owns 3,000 shares of the company’s stock, valued at approximately $104,160. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder Pfizer Inc acquired 50,000 shares of the company’s stock in a transaction dated Tuesday, September 17th. The stock was purchased at an average cost of $18.00 per share, with a total value of $900,000.00. The disclosure for this purchase can be found here. Insiders own 0.09% of the company’s stock.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.05. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The business had revenue of $13.26 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same period in the previous year, the firm posted $0.77 earnings per share. The company’s revenue was down 1.5% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 2.82 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.36 dividend. The ex-dividend date is Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.95%. Pfizer’s payout ratio is presently 48.00%.
Several equities research analysts recently commented on the company. UBS Group reaffirmed a “neutral” rating and issued a $43.00 price target on shares of Pfizer in a report on Monday, August 5th. Zacks Investment Research raised Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target for the company in a report on Tuesday, October 1st. JPMorgan Chase & Co. raised their target price on Pfizer from $37.00 to $46.00 and gave the stock a “neutral” rating in a research note on Thursday, September 19th. They noted that the move was a valuation call. Bank of America started coverage on Pfizer in a research note on Wednesday, October 16th. They set a “neutral” rating and a $37.00 target price for the company. Finally, Credit Suisse Group reissued a “neutral” rating on shares of Pfizer in a research note on Monday, August 12th. Twelve investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Pfizer currently has an average rating of “Hold” and a consensus target price of $44.47.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: Trading Strategy
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.